Veteran Member
Posts: 1434
Liked By: 278
Joined: 06 Mar 02
Followers:
1
Tipsters
Championship:
Player
has
not started
|
BIOSENSORS INT'L GROUP, LTD.
For Q2 FY13, Biosensors reported total revenue, including licensing and royalties, of US$79.8 million, a 28% increase over US$62.2 million in the second quarter of fiscal year 2012 (Q2 FY12). Correspondingly, IVP sales rose to US$61.9 million, up 61% from US$38.4 million in Q2 FY12, driven largely by the full-quarter consolidation of JWMS’ results and continued growth in the sales of the Company’s BioMatrix™ family of DES. Sales revenue of critical care products (CCP) was US$3.6 million, compared to US$3.5 million in the same period last year.
Licensing and royalties revenue was at US$14.3 million, a 29% reduction from the US$20.3 million in Q2 FY12. The reduction in royalty income was largely due to various major DES producers introducing newer products into the Japanese market in the last quarter which created a potential over stocking effect in the market.
Overall operating expense as a percentage of total revenue for the quarter was 41%, compared to 49% in Q2 FY12.
In detail, the quarter’s sales and marketing (S&M) expense was US$18.3 million; general and administrative (G&A) expense was US$9.2 million; research and development (R&D) expense, which included costs for new product development and testing, clinical trials, patent registration and regulatory approval, was US$5.5 million.
For the quarter, the Group’s operating profit was US$33.9 million, representing a 71% year-on-year increase compared to the same period last year.
Excluding exceptional items, which comprise fair value adjustments for warrants, net profit for Q2 FY13 would have been US$29.2 million or basic earnings per share (basic EPS) of 1.69 US cents and diluted earnings per share (diluted EPS) of 1.67 US cents. This compares to a net profit of US$21.5 million or basic EPS of 1.60 US cents and diluted EPS of 1.56 US cents, for Q2 FY12 after excluding the fair value adjustments for warrants.
Including exceptional and non-operating items, net profit for Q2 FY13 was US$28.2 million, or basic EPS of 1.63 US cents and diluted EPS of 1.61 US cents, compared to a net profit of US$22.9 million, or basic EPS of 1.71 US cents and diluted EPS of 1.66 US cents, for Q2 FY12.
|
Main Menu >
Stocks, FX, Cryptocurrencies & Commodities Forum >
BIOSENSORS INT'L GROUP, LTD.
[ 340 Chatters Online
]
1
) 
Find all Topics Started by Solarboy
Find all Posts by Solarboy
Follow / Unfollow
PM Solarboy
07-Nov 2012 Wednesday
7:11 PM (4189 days ago)
1 Likes
Like
08-Nov 2012 Thursday
9:58 AM (4188 days ago)
